ClinicalTrials.gg
Enrolling by invitationNCT04482660Updated May 31, 2025

Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population

An interventional study of Positron emission tomography with 18F-RO6958948 in Healthy and Mild Cognitive Impairment, sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation. Enrolling by invitation at 1 site in Spain. Open to participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Cognitive Dysfunction with a site in Spain — 44 open to participants now, 61 under way, 9 of them phase 3. Cognitive Dysfunction · Spain.

Planned enrollment
63rd of 127
100 · median 100
Started
2021
with 20 others
No phase
91 of 162
27 open now
Primary completion
2025-12
later than 16 of 60 live
Registered
53rd of 162
by date
Lead sponsor
6 of 162
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

Among the 162 studies in Cognitive Dysfunction with a site in Spain, this one is the 63rd largest by planned enrollment of the 127 interventional ones that give a count, is one of 21 that started in 2021, is one of 91 with no phase, reaches primary completion later than 16 of the 60 other live ones, and was the 53rd registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

44 of the 162 studies in Cognitive Dysfunction with a site in Spain are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 45 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Cognitive Dysfunction with a site in Spain, or all of them as a file.
02

Study summary

This study will characterize tau tracer retention by Positron Emission Tomography (PET) as a function of amyloid levels transversally and longitudinally.

Read the detailed description

CROSS-SECTIONAL OBJECTIVES

  • To measure 18F-RO6958948 retention in selected participants of ALFA-related studies as a function of amyloid levels.
  • To study the relation between 18F-RO6958948 retention and amyloid levels.
  • To characterize imaging correlates as a function of tau and amyloid levels.
  • To study the role of tau retention on cognitive performance.
  • To define predictors of tau retention.

LONGITUDINAL OBJECTIVES

  • To measure tau accumulation and spreading in participants of the ALFA-related studies of BBRC as a function of baseline amyloid levels.
  • To study the dynamic relation between tau spreading and amyloid levels longitudinally.
  • To define predictors of tau spreading.
03

Conditions studied

  • Healthy
  • Mild Cognitive Impairment
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. To sign the study form approved by the corresponding authorities.
  2. Men and women that have participated in a BBRC-sponsored study, including the ALFA project (STUDY 45-65 FPM/2012), the ALFA+ cohort study (ALFA - FPM - 0311), the ALFA cognition study (ALFAcognition/BBRC2017) or the BarcelonaBeta Dementia Prevention Research Clinic study (BBRC-DemPrev-2018).
  3. Participants with an available cerebral MRI within the last 12 months not suggestive of radiological incidental findings constituting an exclusion criterion.
  4. Known cognitive status based on the cognitive workup of the BBRC-sponsored studies specified above. Cognitive status should have been determined within the last 12 months.
  5. Known AB and tau status.
  6. Good knowledge of the language and being literate.
  7. Female participants should be or present a negative pregnancy test at the moment of PET acquisition.

Exclusion criteria

Exclusion Criteria:

  1. Presence of psychiatric disorder according to the , 5th Edition (DSM-V) criteria: major depressive disorder, generalized anxiety disorder, schizophrenia and bipolar disorder, as assessed in the BBRC-sponsored studies specified above.
  2. Participants with visual and/or hearing impairment.
  3. History of encephalitis, ictus or seizures excluding feverish convulsions during childhood, as assessed in the BBRC-sponsored studies specified above.
  4. Severe cerebral macrovascular (i.e., multi-stroke) disease or brain tumour (/brain cancer) as verified by MRI.
  5. Previous participation in a clinical study involving an pharmaceutical product within 30 days prior to screening and/or administration of a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study.
  6. Clinically relevant renal or hepatic insufficiency.
  7. Any other clinically important condition that may jeopardize the study or be dangerous for the participant.
  8. Active drug or alcohol abuse, as assessed in the BBRC-sponsored studies specified above.
  9. Previous intolerance to PET studies or known to 18F-RO6958948.
  10. Being pregnant or breast-feeding.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    PET

    Procedure: Positron emission tomography with 18F-RO6958948

Interventions

  • ProcedurePositron emission tomography with 18F-RO6958948

    tau PET ()

06

What researchers measure

Primary outcomes

  1. Prevalence of cerebral tau positivity

    Prevalence of cerebral tau positivity assessed by 18F-RO6958948 PET

    Time frame: at inclusion

  2. tau accumulation and spreading

    To predictors of tau spreading

    Time frame: 2 years

07

Study locations

1 site
  • BarcelonaBeta Brain Research Center
    Barcelona, Barcelona 08005, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Dec 2025, 57 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 57 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 22, 2020
StartActual
Mar 29, 2021
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04482660
Lead sponsor
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Mar 29, 2021
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
May 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion